Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 84Colorectal Neoplasms 42Rectal Neoplasms 40Carcinoma, Non-Small-Cell Lung 27Esophageal Neoplasms 24Esophageal Squamous Cell Carcinoma 23Stomach Neoplasms 19Lung Neoplasms 19Squamous Cell Carcinoma of Head and Neck 17Colonic Neoplasms 17Pancreatic Neoplasms 15Adenocarcinoma Of Esophagus 15Sarcoma 14Prostatic Neoplasms 13Neoplasm Metastasis 13Neoplasms 12Head and Neck Neoplasms 12Ovarian Neoplasms 11Carcinoma, Hepatocellular 11Inflammatory Breast Neoplasms 9Uterine Cervical Neoplasms 8Urinary Bladder Neoplasms 8Osteosarcoma 8Fallopian Tube Neoplasms 8Central Nervous System Neoplasms 8Carcinoma, Intraductal, Noninfiltrating 8Kidney Neoplasms 7Multiple Myeloma 6Glioblastoma 6Carcinoma, Renal Cell 6

Interventions

Gemcitabine 30Mitomycin 25BCG Vaccine 11Docetaxel 10Epirubicin 6erdafitinib 5durvalumab 5Radiotherapy 5dodecyl maltoside 4apaziquone 4tislelizumab 3Cystoscopy 3ALT-803 3viscum album peptide 2pembrolizumab 2disitamab vedotin 2avelumab 2VB4-845 2Therapeutics 2Imiquimod 2Hyaluronic Acid 25-aminolevulinic acid hexyl ester 21-phenyl-3,3-dimethyltriazene 2vocimagene amiretrorepvec 1valrubicin 1tremelimumab 1toripalimab 1pirarubicin 1pemigatinib 1monalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Non-Muscle Invasive Bladder Neoplasms × Neoadjuvant Therapy × Clear all
NCT03636256 2023-08-14

Evaluation of NanoDoceĀ® in Participants With Urothelial Carcinoma

NanOlogy, LLC

Phase 1/2 Completed
36 enrolled 18 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urogenital Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔